Policy & Regulation
Intezyne awarded SEBIO's 'Deal of the Year' in Pinehurst, NC
23 November 2017 -

Biopharmaceutical company Intezyne revealed on Wednesday the completion of the USD10m Series A preferred round led by Gaston Capital based in North Carolina.

This USD10m Series A preferred round was reportedly recognized as the 'Deal of the Year: Initial Funding' at the 19th Annual Southeast BIO (SEBIO) Investor & Partnering Forum, held in Pinehurst, NC from 14-16 November 2017.

The company said it has two clinical-stage programmes: IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor for pancreatic, gastric and BRAF-mutated cancers in combination with existing anti-cancer therapies, and IT-141, a novel topoisomerase I (TOP-I) inhibitor for colorectal and breast cancers.

Additionally, IT-139 was granted an Orphan Drug Designation (ODD) in early 2017 and the company expects to initiate parallel Phase 1/2 studies of IT-139 in pancreatic and gastric cancer in mid-2018. Recent pharmacokinetic (PK) data from its ongoing Phase 1 clinical study of IT-141 showed successful delivery of SN-38 far in excess of both Pfizer's Camptosar (irinotecan) and Merrimack's Onivyde (liposomal irinotecan), the latter of which was acquired by Ipsen in early 2017.